Aug 13, 2026 07:00AM
Jun 2, 2026 07:05PM
Jun 2, 2026 07:05PM
May 28, 2026 07:05AM
May 19, 2026 07:05AM
May 19, 2026 07:05AM
May 13, 2026 06:50AM Zenas BioPharma begins Phase 1 trial of oral IL-17 inhibitor ZB021
May 13, 2026 06:50AM
May 13, 2026 06:00AM
Mar 27, 2026 12:13AM
Mar 27, 2026 12:12AM
Mar 26, 2026 04:01PM
Mar 26, 2026 04:01PM
Mar 16, 2026 07:00AM Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 9, 2026 07:05AM
Feb 9, 2026 07:05AM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM
Dec 16, 2025 06:58AM
Dec 15, 2025 07:05AM
Dec 15, 2025 07:05AM Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
Nov 12, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:15AM Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
Sep 2, 2025 07:05AM

329,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All